259 related articles for article (PubMed ID: 30585649)
1. Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients.
Kurihara Y; Yamagami J; Funakoshi T; Ishii M; Miyamoto J; Fujio Y; Kakuta R; Tanikawa A; Aoyama Y; Iwatsuki K; Ishii N; Hashimoto T; Nishie W; Shimizu H; Kouyama K; Amagai M
J Dermatol; 2019 Feb; 46(2):124-130. PubMed ID: 30585649
[TBL] [Abstract][Full Text] [Related]
2. Rituximab therapy for intractable pemphigus: A multicenter, open-label, single-arm, prospective study of 20 Japanese patients.
Yamagami J; Kurihara Y; Funakoshi T; Saito Y; Tanaka R; Takahashi H; Ujiie H; Iwata H; Hirai Y; Iwatsuki K; Ishii N; Sakurai J; Abe T; Takemura R; Mashino N; Abe M; Amagai M
J Dermatol; 2023 Feb; 50(2):175-182. PubMed ID: 36196051
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
4. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].
Kasperkiewicz M; Zillikens D
Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.
Kasperkiewicz M; Shimanovich I; Ludwig RJ; Rose C; Zillikens D; Schmidt E
J Am Acad Dermatol; 2011 Sep; 65(3):552-558. PubMed ID: 21641080
[TBL] [Abstract][Full Text] [Related]
6. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of severe refractory pemphigus vulgaris with rituximab].
Pitarch G; Sánchez-Carazo JL; Pardo J; Torrijos A; Roche E; Fortea JM
Actas Dermosifiliogr; 2006; 97(1):48-51. PubMed ID: 16540052
[TBL] [Abstract][Full Text] [Related]
8. IgM Deficiency in Autoimmune Blistering Mucocutaneous Diseases Following Various Treatments: Long Term Follow-Up and Relevant Observations.
Ahmed AR; Aksoy M
Front Immunol; 2021; 12():727520. PubMed ID: 34646266
[TBL] [Abstract][Full Text] [Related]
9. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.
Cho HH; Jin SP; Chung JH
J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542
[TBL] [Abstract][Full Text] [Related]
10. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
Londhe PJ; Kalyanpad Y; Khopkar US
Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients.
Goh MS; McCormack C; Dinh HV; Welsh B; Foley P; Prince HM
Br J Dermatol; 2007 May; 156(5):990-6. PubMed ID: 17355229
[TBL] [Abstract][Full Text] [Related]
12. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication.
Kolesnik M; Becker E; Reinhold D; Ambach A; Heim MU; Gollnick H; Bonnekoh B
J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):771-80. PubMed ID: 23651052
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.
Lamberts A; Euverman HI; Terra JB; Jonkman MF; Horváth B
Front Immunol; 2018; 9():248. PubMed ID: 29520266
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in treatment-resistant autoimmune blistering skin disorders.
Schmidt E; Bröcker EB; Goebeler M
Clin Rev Allergy Immunol; 2008 Feb; 34(1):56-64. PubMed ID: 18270859
[TBL] [Abstract][Full Text] [Related]
15. Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study.
Russo I; Miotto S; Saponeri A; Alaibac M
Expert Opin Biol Ther; 2020 Jun; 20(6):673-678. PubMed ID: 32027810
[No Abstract] [Full Text] [Related]
16. Low-Dose Rituximab for Bullous Pemphigoid. Protocol and Single-Center Experience.
Suárez-Carantoña C; Jiménez-Cauhé J; González-García A; Fernández-Guarino M; Asunción Ballester M
Actas Dermosifiliogr; 2023 Jan; 114(1):T62-T68. PubMed ID: 36368587
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Rituximab for Bullous Pemphigoid. Protocol and Single-Center Experience.
Suárez-Carantoña C; Jiménez-Cauhé J; González-García A; Fernández-Guarino M; Asunción Ballester M
Actas Dermosifiliogr; 2023 Jan; 114(1):62-68. PubMed ID: 35868546
[TBL] [Abstract][Full Text] [Related]
18. Durable remission of pemphigus with a fixed-dose rituximab protocol.
Heelan K; Al-Mohammedi F; Smith MJ; Knowles S; Lansang P; Walsh S; Shear NH
JAMA Dermatol; 2014 Jul; 150(7):703-8. PubMed ID: 24500264
[TBL] [Abstract][Full Text] [Related]
19. Bullous Diseases.
Corbaux C; Joly P
Curr Probl Dermatol; 2018; 53():64-69. PubMed ID: 29131038
[TBL] [Abstract][Full Text] [Related]
20. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases.
Hertl M; Zillikens D; Borradori L; Bruckner-Tuderman L; Burckhard H; Eming R; Engert A; Goebeler M; Hofmann S; Hunzelmann N; Karlhofer F; Kautz O; Lippert U; Niedermeier A; Nitschke M; Pfütze M; Reiser M; Rose C; Schmidt E; Shimanovich I; Sticherling M; Wolff-Franke S
J Dtsch Dermatol Ges; 2008 May; 6(5):366-73. PubMed ID: 18201220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
